Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

Bevacizumab (Avastin, Roche [originator] and biosimilars) with fluoropyrimidine-based chemotherapy is indicated for the 'treatment of adult patients with metastatic carcinoma of the colon or rectum'.

The dosage schedule is available in the summary of product characteristics for bevacizumab (originator) in combination with fluoropyrimidine-based chemotherapy.

The list price for bevacizumab (originator) for a 100‑mg vial is £242.66, and a 400‑mg vial is £924.40. The list price of biosimilars range from £202.50 to £242.66 for a 100‑mg vial and from £810.00 to £924.40 for a 400‑mg vial (excluding VAT; BNF online, accessed November 2025).

Regionally available price reductions for bevacizumab (originator and biosimilars) are in place with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.

A Carbon Reduction Plan for UK carbon emissions is not included because there are multiple companies that manufacture bevacizumab.